Placid Jover Sells 6,053 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock

Key Points

• Teva Pharmaceutical Industries insider Placid Jover sold 6,053 shares for a total of $91,763.48, reducing their ownership by 47.19%.
• The company's stock price experienced a slight increase and was trading at $15.72, with a market cap of $18.03 billion.
• Teva reported an EPS of $0.66 for its last quarter, exceeding analysts' estimates, though revenue fell short at $4.18 billion.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.05 during trading hours on Friday, reaching $16.34. 9,533,492 shares of the company traded hands, compared to its average volume of 13,038,851. The stock has a market capitalization of $18.74 billion, a P/E ratio of -102.13, a P/E/G ratio of 0.97 and a beta of 0.62. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The business has a fifty day moving average price of $16.72 and a 200-day moving average price of $16.39.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the prior year, the firm earned $0.61 EPS. The company's revenue for the quarter was up .3% on a year-over-year basis. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in the business. Duquesne Family Office LLC boosted its holdings in Teva Pharmaceutical Industries by 65.4% during the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock worth $228,702,000 after buying an additional 5,882,350 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after buying an additional 134,705 shares during the last quarter. Financial Sense Advisors Inc. increased its position in Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock worth $6,231,000 after purchasing an additional 157,421 shares during the last quarter. King Wealth Management Group increased its position in Teva Pharmaceutical Industries by 1,106.9% during the first quarter. King Wealth Management Group now owns 175,000 shares of the company's stock worth $2,690,000 after purchasing an additional 160,500 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Teva Pharmaceutical Industries by 804.7% during the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock worth $1,037,000 after buying an additional 60,016 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TEVA. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Truist Financial started coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.